bluuebunny/crossref_metadata_2025_split huggingface dataset:
Self-reported decreases in the purchases of selected unhealthy foods resulting from the implementation of warning labels in Mexican youth and adult population
Authors: Contreras-Manzano Alejandra , White Christine M. , Nieto Claudia , Quevedo Kathia L. , Vargas-Meza Jorge , Hammond David , Thrasher James F. , Barquera Simón , Jáuregui Alejandra 
Published: June 2024

Abstract
Background
Front-of-package nutritional warning labels (WLs) are designed to facilitate identification and selection of healthier food choices. We assessed self-reported changes in purchasing different types of unhealthy foods due to WLs in Mexico and the association between the self-reported reductions in purchases of sugary beverages and intake of water and sugar-sweetened beverages.

Methods
Data came from 14 to 17 year old youth (n = 1,696) and adults ≥ 18 (n = 7,775) who participated in the Mexican arm of the 2020–2021 International Food Policy Study, an annual repeat cross-sectional online survey. Participants self-reported whether the WLs had influenced them to purchase less of each of nine unhealthy food categories due to WLs. Among adults, a 23-item Beverage Frequency Questionnaire was used derive past 7-day intake of water and sugary beverages analyzed to determine the relationship between self-reported reductions in purchasing sugary drinks due to the WLs. Multilevel mixed-effects logistic regression models were fitted to estimate the percentage of participants who self-reported reducing purchases within each food group, and overall. Sociodemographic characteristics associated with this reduction were investigated as well.

Results
Overall, 44.8% of adults and 38.7% of youth reported buying less of unhealthy food categories due to the implementation of WL, with the largest proportion reporting decreased purchases of cola, regular and diet soda. A greater impact of WLs on the reported purchase of unhealthy foods was observed among the following socio-demographic characteristics: females, individuals who self-identified as indigenous, those who were overweight, individuals with lower educational levels, those with higher nutrition knowledge, households with children, and those with a significant role in household food purchases. In addition, adults who reported higher water intake and lower consumption of sugary beverages were more likely to report reduced purchases of sugary drinks due to the WLs. Adults who reported greater water intake and lower sugary beverages intake were significantly more likely to report buying fewer sugary drinks due to the WLs.

Conclusion
Our findings suggest that implementation of WLs has reduced perceived purchases of unhealthy foods in Mexico. These results underscore the potential positive impact of the labeling policy particularly in subpopulations with lower levels of education and among indigenous adults.
New evidence for a role of DANCR in cancers: a comprehensive review
Authors: Yuan Rong , Xu Zhao-jun , Zhang Sheng-kang , Cao Xian-ya , Dai Ai-guo , Song Lan 
Published: June 2024

AbstractCancer remains a leading cause of mortality and poses a substantial threat to public health. Studies have revealed that Long noncoding RNA DANCR is a cytoplasmic lncRNA whose aberrant expression plays a pivotal role in various cancer types. Within tumour biology, DANCR exerts regulatory control over crucial processes such as proliferation, invasion, metastasis, angiogenesis, inflammatory responses, cellular energy metabolism reprogramming, and apoptosis. By acting as a competitive endogenous RNA for miRNAs and by interacting with proteins and mRNAs at the molecular level, DANCR contributes significantly to cancer progression. Elevated DANCR levels have also been linked to heightened resistance to anticancer drugs. Moreover, the detection of circulating DANCR holds promise as a valuable biomarker for aiding in the clinical differentiation of different cancer types. This article offers a comprehensive review and elucidation of the primary functions and molecular mechanisms through which DANCR influences tumours.
Potential long-term, global effects of enhancing the domestic terrestrial carbon sink in the United States through no-till and cover cropping
Authors: Weber Maridee , Wise Marshall , Lamers Patrick , Wang Yong , Avery Greg , Morris Kendalynn A. , Edmonds Jae 
Published: June 2024

Abstract
Background
Achieving a net zero greenhouse gas United States (US) economy is likely to require both deep sectoral mitigation and additional carbon dioxide removals to offset hard-to-abate emissions. Enhancing the terrestrial carbon sink, through practices such as the adoption of no-till and cover cropping agricultural management, could provide a portion of these required offsets. Changing domestic agricultural practices to optimize carbon content, however, might reduce or shift US agricultural commodity outputs and exports, with potential implications on respective global markets and land use patterns. Here, we use an integrated energy-economy-land-climate model to comprehensively assess the global land, trade, and emissions impacts of an adoption of domestic no-till farming and cover cropping practices based on carbon pricing.

Results
We find that the adoption of these practices varies depending on which aspects of terrestrial carbon are valued. Valuation of all terrestrial carbon resulted in afforestation at the expense of domestic agricultural production. In contrast, a policy valuing soil carbon in agricultural systems specifically indicates strong adoption of no-till and cover cropping for key crops.

Conclusions
We conclude that under targeted terrestrial carbon incentives, adoption of no-till and cover cropping practices in the US could increase the terrestrial carbon sink with limited effects on crop availability for food and fodder markets. Future work should consider integrated assessment modeling of non-CO2 greenhouse gas impacts, above ground carbon storage changes, and capital and operating cost considerations.
Association between hyperglycemia and the development of chemotherapy-induced peripheral neuropathy among patients with breast cancer.
Authors: Klahr Miriam Pearl , Faheem Khadija , Raghunathan Rohit R. , Hershman Dawn L. , Accordino Melissa Kate 
Published: June 2024

12125 Background: Poorly controlled diabetes is a predictor of chemotherapy induced peripheral neuropathy (CIPN), and hyperglycemia (HG) may mediate CIPN risk. The association between CIPN and HG is not well studied. Our objective was to evaluate the association between HG and CIPN development. Methods: The CONTRoL trial was a phase IIB randomized adaptive sequential selection trial that evaluated cryotherapy vs. compression vs. placebo to prevent CIPN in patients with Stage I-III breast cancer during taxane therapy. Patients completed the Functional Assessment of Cancer Therapy Neurotoxicity (FACT-NTX) survey at baseline, week-12, and week-24. CIPN development was defined as ≥ 5-point increase in FACT-NTX from baseline. We included patients who completed FACT-NTX at baseline and week-12. HG (any glucose ≥ 140 mmol/L) was assessed via chart review of random glucose laboratory results collected from time of taxane initiation through week-24. Patients were divided into two groups based on CIPN development (yes/no). For each group we calculated the proportion of patients with HG, and mean glucose at baseline, week-12 and week-24 with values obtained +/-7 days of specified timeframe; 95% confidence intervals were constructed. Results: Sixty-three patients participated in the CONTRoL study and 59 patients were included in this analysis. All 59 patients had ≥1 recorded glucose value during the 24-week period (n= 410 total values), with a median of 6 values (range 1-12) per patient. When comparing patients who did and did not develop CIPN, 29.4% vs. 20.0% were Black (p=0.72), 41.2% vs. 52.0% were Hispanic/Latino (p=0.69), 17.6% vs. 8.0% had diabetes (p=0.49) and 64.7% vs. 48.0% received docetaxel (p=0.31). There were higher rates of HG, 47.1% vs. 36.0%, in patients who developed CIPN vs. those who did not (p=0.56). Mean glucose was higher in patients who developed CIPN compared to those who did not at all timepoints (Table). Conclusions: In this secondary analysis, we found that almost half of patients with CIPN had HG compared to about a third of patients without CIPN, and that patients with CIPN had higher mean glucose at all timepoints compared to patients without CIPN. Due to the small sample size, differences were not statistically significant, but notable trends were observed. Further research is needed to confirm this finding and evaluate the impact of glucose lowering interventions on preventing the development of CIPN. Clinical trial information: NCT03873272 . [Table: see text]
Development of clinically accessible nomograms to predict risk of brain metastases at baseline and follow-up in patients with non-small cell lung cancer.
Authors: Mansouri Alireza , Wilding Hannah E. , Mikolajewicz Nicholas , Bhanja Debarati , Moeckel Camille , Ozair Ahmad , Hamidi Nima , Tankam Cyril , Stoltzfus Mason , Baroz Angel Ray , Stahl Caleb , Trifoi Mara , Dudek Cain , Ahluwalia Manmeet Singh 
Published: June 2024

2035 Background: Brain metastases (BM) are a common complication in non-small cell lung cancer (NSCLC). Reliable models predicting risk of BM development are lacking, hindering effective CNS screening and patient prognostication. In the era of precision medicine, these are important gaps in our knowledge. The aims of this study were to 1) evaluate published BM risk-stratification algorithms, and 2) develop nomograms to predict BM incidence. Methods: Using a retrospective cohort of NSCLC patients from Penn State Health (2011-2020), we 1) evaluated the performance of published BM risk-stratification algorithms systematically identified, and 2) developed nomograms to predict risk of BM incidence. For Aim 1, published algorithms were benchmarked using AUROCs calculated from logistic regression models. For Aim 2, cox-proportional hazard models were trained using L1-regularization, and nomograms were constructed to predict BM risk at 6-month, 1-year, and 2-year follow up. Two separate nomograms were developed: Model T0 used only clinical and imaging data available at time of diagnosis, while Model T1 leveraged additional molecular characteristics and treatment history. All models were trained using 70% of data and tested using 30% of data. Time-dependent AUROC metrics for nomograms were calculated using a cumulative sensitivity and dynamic specificity-based estimator. Results: Our cohort included 1904 patients (median age 68, range: 38 to 94 years, BM incidence 22.8%). Aim 1: 12 published algorithms were identified that used variables consistently available in patient charts. Among these, the Zhang 2021 model was the best predictor of cumulative BM risk (AUROC [95% CI] = 0.89 [0.85-0.93]). Aim 2: Model T0 was trained using age at diagnosis and clinical TNM stage and predicted BM incidence at 6-month, 1-year and 2-year follow up with AUROCs of 0.87, 0.85, and 0.87, respectively. Model T1 was trained with additional predictors, including number of extra-cranial metastatic sites, treatment history (e.g., radiation, surgery, chemotherapy, etc.), and mutation profile (EGFR, KRAS, ALK, BRAF), and achieved AUROCs of 0.90, 0.89, and 0.91 at 6-month, 1-year and 2-year follow up, respectively. Distant metastases at time of NSCLC diagnosis (HR [95% CI] = 3.38 [2.28, 4.99]) and number of extra-cranial metastatic sites (HR [95% CI] = 1.75 [1.54, 1.99] per each additional metastasis) were the strongest independent predictors of BM risk. Conclusions: Based on one of the largest NSCLC cohorts to date, we have developed clinically accessible nomograms for prediction of BM development. This tool can be readily applied toward prognostic modeling and risk stratification, refinement of practice guidelines for CNS screening, and patient counseling.
Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200, in patients with advanced solid tumors.
Authors: Chenard-Poirier Maxime , Almhanna Khaldoun , Lim Darren Wan-Teck , El-Khoueiry Anthony B. , Samol Jens , Ryoo Baek-Yeol , Yong Hong Jung , MENG ROBIN , Abbadessa Giovanni , Masciari Serena , Kefsi Asma , Zhang Yiding , Guillemin-Paveau Helene , Pasquier Benoit , Lepine Lucie , Dumbrava Ecaterina Elena 
Published: June 2024

2579 Background: SAR444200 is a novel NANOBODY T cell engager that simultaneously binds TCRαβ and glypican-3 (GPC3) to co-engage T cells with GPC3-expressing tumor cells, resulting in T cell-dependent cellular cytotoxicity. Here we present updated safety, pharmacokinetics (PK) and biomarker data from 6 and 5 dose levels (DL), respectively in patients with advanced solid tumors in the dose escalation cohort (Part 1A) from the first-in-human Phase 1/2 trial (NCT05450562). Methods: This ongoing Phase 1/2 trial evaluated open label, intravenously administered SAR444200 (every week with lead-in doses) at DL1 (3 mg), DL1A (1 mg), DL2A (2.5 mg), DL3A (4.5 mg), DL4A (18 mg), and DL5A (36 mg) in adult patients with GPC3+ solid tumors. On study imaging was performed every 9 weeks after the date of first infusion of SAR444200. Whole blood samples were collected to assess the plasma concentrations of SAR444200 and for biomarker analysis. PK analysis was performed with electrochemiluminescence-based total PK assay using Meso Scale Discovery platform. Anti-drug antibody (ADA) monitoring was performed using a PandA assay. Results: As of 19 January 2024, a total of 24 patients with GPC3+ solid tumors received SAR444200, 4 patients per DL (DL1, DL1A, DL2A, DL3A, DL4A, DL5A). Most of the patients (17 patients, 71%) had hepatocellular carcinoma. No dose-limiting toxicities were observed. Twenty-two patients (92%) reported treatment-related adverse events (TRAEs) of any grade, including three patients with a serious TRAE (2 events with hospitalization prolongation for a Grade 1 and 2 cytokine release syndrome [CRS] that recovered completely without and with Tocilizumab, respectively, 1 event with pneumonitis Grade 3). All CRS (19 patients, 79%) and infusion-related reaction (7 patients, 29%) were Grade 1 or 2. Cmax was observed at the end or shortly after completion of infusion. The maximum ADA titer, though high, stabilized despite the target dose increased from Cycle 2. Biomarker analysis showed an increase of interleukin-6 and interferon gamma during lead-in doses, supporting CRS. Cytokines declined after Cycle 1. Among 14 HCC patients with baseline alpha-fatal protein (AFP) higher than 20 ng/ml, 4 (29%) had at least a 20% AFP decrease on treatment. Two patients (both with HCC) have been on study drug for more than 6 months. Conclusions: These results suggest that SAR444200 is tolerable at the tested dose levels in patients with GPC3+ advanced solid tumors. Dose escalation continues at this time. Clinical trial information: NCT05450562 .
Development of an mRNA therapeutic vaccine for virally driven Merkel cell carcinoma.
Authors: Frey Alexander , Perry Curtis , Olino Kelly , Ishizuka Jeffrey Joseph 
Published: June 2024

2637 Background: Merkel Cell Carcinoma (MCC) is a neuroendocrine skin cancer associated with integration of a truncated form of Merkel Cell Polyomavirus Large T Antigen (LTA) in most U.S. cases. LTA is a robust antigen and its expression is required for proliferation of MCC, rendering it an ideal target for an mRNA therapeutic vaccine approach. Methods: B16-F10 murine melanoma cells that express the truncated LTA oncoprotein were generated for use as an in vivoMCC model. In vitro transcription was used to create an optimized mRNA coding for the LTA and was encapsulated in lipid nanoparticles for intramuscular injection. LTA expressing tumor cells were injected subcutaneously in C57BL/6 mice and treated with LTA mRNA or placebo +/- anti-PD1 antibodies. Tumor growth and survival were tracked, and flow cytometry of ex-vivo tumor samples was used to characterize immune infiltration. Separate mice were treated with a three-dose series of LTA mRNA or placebo 60 days prior to tumor cell injection, and tumor growth and survival were measured. MCC patient PBMCs were collected and used as a model for human in vitro vaccination. Monocyte derived dendritic cells were transfected with LTA mRNA or placebo and used to stimulate the remainder of the PBMC pool every seven days. LTA specific T cell proportion, activation markers, cytokine release, and MCC specific tumor cell killing were measured. Results: Treatment with LTA mRNA suppressed tumor growth compared to placebo (day 21 mean volume 47.28 mm3 vs. 575.12mm3 P<.001) and prolonged median survival (46 vs. 24 days P<.001). Combination treatment with anti-PD1 resulted in 100% tumor regression compared to 50% with anti-PD1 only (median survival 117 days) and 0% with placebo (median survival 28.5 days). Flow cytometry of ex vivotumors from LTA mRNA treated mice revealed increased immune infiltration (mean CD45+ 11.56% vs. 7.81% P=.037) with an increased proportion of CD3+ cells (mean 69.74% vs. 57.36% P=.0013) and CD8+ cells with increased cytotoxic markers (MFI GZMB 26785 vs. 13607 P=.0026). Prophylactic vaccination with LTA mRNA resulted in 80% tumor rejection vs. 0% with placebo (median survival undefined vs. 31.5 days P<.0001). Furthermore, in the prophylactic vaccination group there were no detectable tumors until day 60 following tumor challenge. In vitro vaccination of patient PBMCs resulted in expansion of LTA tetramer specific CD8+ T cells by day 10 (0.3% vs. 0.077%). Exposure of treated cells to antigen loaded DCs resulted in increased IFNg release by day 10 (21.78ng/mL vs. 5.35ng/mL P<.0001) and increased specific MCC tumor cell killing on day 14 (mean tumor death 9.14% vs. 4.18% P=.0001). Conclusions: Therapeutic vaccination with LTA targeting mRNA suppresses tumor growth and prolongs survival in vivo by increasing infiltration of cytotoxic immune populations. In vitrohuman vaccination increases the proportion LTA specific CD8+ T cells, IFNg release, and specific killing of MCC cells.
Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors.
Authors: Liu Jiajian , Zhou Caicun , Li Wei 
Published: June 2024

2639 Background: LB1410 is a recombinant humanized anti-PD-1/TIM-3 bispecific antibody (BsAb) developed by L&L Biopharma Co., Ltd, which blocks the immune checkpoint PD-1 and TIM-3-mediated immunosuppressive signal pathways, and showed better T/DC cell activity and in vivo anti-tumor efficacy compared to TIM-3 and PD-1 antibody combination in preclinical studies. Here we report the results of the first-in-human, multicenter, open-label, phase I trial of LB1410 monotherapy in pts with advanced solid tumors ( Keyplus-001 ). Methods: Eligible pts were ≥ 18 yr old with ECOG PS 0-1 and previous treatment. Dose escalation cohorts ranged from 0.001 mg/kg to 20 mg/kg IV Q2W: 0.001mg/kg-1mg/kg in an accelerated titration design, and 3 mg/kg-20 mg/kg using traditional 3+3 design. The primary objective is safety, including dose-limiting toxicities (DLTs). Secondary/exploratory objectives include efficacy, pharmacokinetics (PK), and immunogenicity. Data cutoffs were January 5, 2024 for safety, and January 25, 2024 for efficacy. Results: In total, 52 pts received LB1410 from 0.001 mg/kg to 20 mg/kg as of Jan 5, 2024, median age 58 yr, 69% male. All of patients enrolled had multiple organ metastases or multiple metastases in a single organ, and were heavily treated with anti-tumor treatment, 36/52 (69.2%) were resistant to or refractory to PD-1/PD-L1 inhibitors, and 16/52 (30.8%) were MSS CRC. Treatment related AEs (TRAEs) occurred in 65.4% of pts. The most common TRAE was anemia (19.2%). 2 patients developed Gr3 hypokalemia. There were no DLTs. Tumor response evaluation were available in 40 pts: 14 had stable disease, 25 had progression, and 1 was not evaluable. Target lesion shrinkage was observed in 9 pts, including one patient's sum of target lesion reduced by 48.7% from baseline. Of 14 pts who had stable disease, there were 2 pts with stable disease lasting for more than 6 months. PK was generally dose proportional within 1 mg/kg~15 mg/kg, with t1/2 ~4.12 days in 10 mg/kg, and t1/2 ~4.77 days in 15 mg/kg. Of the 22 subjects tested for ADA, only one produced ADA for LB1410, the positive rate was 4.5%. Antidrug antibodies had limited impact on PK. As of Jan 5, 2024, 39 pts remained on the study; updated data will be presented. Conclusions: LB1410 has manageable safety and shows preliminary efficacy. Additional dose and efficacy expansion study is ongoing in immunotherapy-naive pts with MSS CRC and pts who are resistant to immunotherapy. Clinical trial information: NCT05357651 .
Primary analysis of a phase 1/2 study of LM-101: An anti-SIRPα antibody as a single agent in patients with advanced malignancies.
Authors: Xia Yi , Zhou Fuling , Kong Liang , Fei Da , Bai Tian , Qin Xia , Fang Xiaojie , Ji Dongmei , Cai Qingqing 
Published: June 2024

2640 Background: LM-101 is a humanized monoclonal antibody which binds to both V1 and V2 isoforms of SIRPα that expressed on macrophages and dendritic cells and enables phagocytosis of tumor cells. LM-101 has shown optimal pre-clinical safety profiles and promising anti-tumor activity in animal models. Here we report the primary analysis of the single agent dose escalation results of a phase 1/2 study (NCT05615974). Methods: This is an open-label, phase 1/2, first-in-human, multicenter dose escalation study with dose expansion evaluating safety and clinical activity of LM-101 as a single agent in patients with advanced malignancies. Eligible patients were aged ≥ 18 years with advanced solid tumors or relapsed/refractory lymphoma who had progressed on standard therapy, or intolerable to the available standard therapy, or had no available standard therapy for treatment. In the dose escalation part, enrolled patients were administered with LM-101 intravenously every three weeks at dose levels of 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, and 40 mg/kg as per traditional 3+3 design. The objectives for this dose escalation part included safety and clinical activity as per RECIST v1.1 criteria or Lugano 2014 criteria. Results: As of January 24, 2024, 17 patients were enrolled in the single agent dose escalation part. No DLT was observed at all dose levels and MTD for single agent was not reached. The most frequent adverse event (AE) related to the study drug was lymphocyte counts decreased. Two patients experienced grade ≥ 3 AEs which were related to LM-101. Out of 16 patients from single agent dose-escalation groups who had at least one time tumor assessment post treatment, one patient achieved complete response (CR), one patient achieved partial response (PR) and five patients achieved stable disease (SD). Conclusions: LM-101 monotherapy showed excellent safety profile and promising anti-tumor activity in patients with advanced malignancies. Further investigation of LM-101 as a single agent and in combination with other anti-tumor agents are ongoing. Clinical trial information: NCT05615974 .